Evaluation of Preventive Effect of Intravenous Trans Sodium Crocetinate on Contrast-Induced Nephropathy

Evaluation of Preventive Effect of Intravenous Trans Sodium Crocetinate on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angioplasty : A randomized placebo-controlled triple-blind clinical trail

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20081019001369N8

Enrollment

152

Registered

2022-04-14

Start date

2022-04-04

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Certain current complications following acute myocardial infarction. Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28 day period)

Interventions

Intervention 1: Intervention group: Patients undergoing elective angioplasty who, in addition to the standard preventive measure of CIN, recieve TSC at dose of 0.5 mg / kg as an injection, 5 minutes b

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Candidates for outpatient angioplasty

Exclusion criteria

Exclusion criteria: The presence of ESRD requires dialysis before angiography Presence of underlying diseases leading to acute renal failure regardless of contrast-induced acute renal failure Existence of active tumor History of exposure to intravenous contrast agents in the last 14 days for other reasons Existence of heart failure or cardiogenic shock Taking drugs interacting kidney function

Design outcomes

Primary

Measure	Time frame
Effect of TSC on the occurrence of acute kidney injury. Timepoint: during 5 days. Method of measurement: mehran score.	—

Secondary

Measure	Time frame
Effect of TSC administration on creatinine clearance level. Timepoint: days 0 , 1 , 2 ,5. Method of measurement: laboratory evaluation.;Effect of TSC administration on serum creatinine and BUN level. Timepoint: days 0 , 1 , 2 ,5. Method of measurement: laboratory evaluation.;Effect of TSC administration on cystatin C level. Timepoint: days 0 , 1 , 2. Method of measurement: laboratory evaluation.;Effect of TSC administration on hs-CRP level. Timepoint: days 0 , 5. Method of measurement: laboratory evaluation.;Effect of TSC administration on 24hours urine analysis test. Timepoint: days 0 , 1 , 2 ,5. Method of measurement: laboratory evaluation.;Effect of TSC administration on mehran score. Timepoint: days 0 , 5. Method of measurement: laboratory evaluation.;Effect of TSC administration on MDA test. Timepoint: days 0 , 5. Method of measurement: laboratory evaluation.	—

Measure

Time frame

Effect of TSC administration on creatinine clearance level. Timepoint: days 0 , 1 , 2 ,5. Method of measurement: laboratory evaluation.;Effect of TSC administration on serum creatinine and BUN level. Timepoint: days 0 , 1 , 2 ,5. Method of measurement: laboratory evaluation.;Effect of TSC administration on cystatin C level. Timepoint: days 0 , 1 , 2. Method of measurement: laboratory evaluation.;Effect of TSC administration on hs-CRP level. Timepoint: days 0 , 5. Method of measurement: laboratory evaluation.;Effect of TSC administration on 24hours urine analysis test. Timepoint: days 0 , 1 , 2 ,5. Method of measurement: laboratory evaluation.;Effect of TSC administration on mehran score. Timepoint: days 0 , 5. Method of measurement: laboratory evaluation.;Effect of TSC administration on MDA test. Timepoint: days 0 , 5. Method of measurement: laboratory evaluation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactarash gholoobi

Mashhad University of Medical Sciences

gholoobiA@mums.ac.ir+98 51 3180 1193

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026